

Predictors of postoperative urinary tract infection following holmium laser enucleation of prostate

Mohamed Elsaqa^{1,2}, Katherine Dowd¹, Amr El Mekresh¹, Karen M. Doersch³, Marawan M. El Tayeb¹

¹Division of Urology, Department of Surgery Baylor Scott & White Health, CTX, Temple, TX, United States;

²Alexandria University Faculty of Medicine, Alexandria, Egypt; ³Department of Urology, University of Rochester Medical Center, Rochester, NY, United States

Cite as: Elsaqa M, Dowd K, El Mekresh A, et al. Predictors of postoperative urinary tract infection following holmium laser enucleation of prostate. *Can Urol Assoc J* 2023 August 03; Epub ahead of print. <http://dx.doi.org/10.5489/cuaj.8269>

Published online August 03, 2023

Corresponding author: Dr. Mohamed Elsaqa, Division of Urology, Department of Surgery, Baylor Scott & White Health, Temple, TX, United States; mohamed.elsaqa@alexmed.edu.eg

ABSTRACT

Introduction: Storage urinary symptoms and urinary tract infection (UTI) are among the most common complications following holmium laser enucleation of prostate (HoLEP). We aimed to study the incidence and risk factors for storage urinary symptoms and early UTI following HoLEP.

Methods: A prospectively maintained database was reviewed for patients who underwent HoLEP over a five-year period at a single tertiary center. Patient demographics, preoperative, operative, and postoperative characteristics, as well as infection rates, were obtained and analyzed using the appropriate statistical methods.

Results: Of a total of 514 patients who underwent HoLEP, 473 patients with complete followup data were included. Mean (\pm standard deviation) age and median (interquartile range) prostate volume were 72 ± 9.1 years and 89 (68–126) g, respectively. Preoperative positive urine culture and urine retention were seen in 28.5% (n=135) and 23.46% (n=111) of patients, respectively. At six-week followup, irritative urinary symptoms

KEY MESSAGES

- HoLEP has been a steadily growing MIS option for management of BPH.
- UTI is one of the main complications following transurethral surgeries, including HoLEP.
- Irritative voiding symptoms are consistently a main complaint post-HoLEP that are sometimes difficult to distinguish from postoperative UTI.
- In our study, irritative urinary symptoms were seen in 32.3% of patients, while 13.5% of patients had true postoperative UTI.
- UTI risk factors identified were preoperative UTI, obesity, weak grip strength within preoperative frailty assessment, and postoperative incontinence.

were seen in 32.3% (n=153) of patients, while 13.5% (n= 64) of patients had positive urine culture. Bivariate and multivariate analysis showed that factors associated with significant higher rate of postoperative UTI at six weeks were high body mass index (BMI_ (p= 0.023), weak grip strength within preoperative frailty assessment (p=0.042), positive preoperative urine culture (p=0.025), and postoperative incontinence (p=0.002).

Conclusions: Storage urinary symptoms are common complaints post-HoLEP; however, it may be caused by an inflammatory rather than infective process in a significant percentage of patients. Possible predictors of UTI after HoLEP are high BMI, preoperative positive urine culture, higher frailty scale, and postoperative urinary incontinence.

INTRODUCTION

Holmium laser enucleation of the prostate (HoLEP) combined with mechanical morcellation has been a steadily growing surgical option for management of benign prostatic hyperplasia (BPH). HoLEP has shown low overall complication rate, durable symptom relief, very low reoperation rate, and high patient satisfaction rate. (1-2) HoLEP has become an effective and safe alternative for managing variable size prostates rivaling transurethral resection of prostate (TURP) or simple prostatectomy. (3-5)

The most common complications related to HoLEP include retrograde ejaculation, transient storage voiding symptoms, postoperative urinary tract infection (UTI), and transient urinary incontinence. (6-7) Storage voiding symptoms are consistently a main complaint early following HoLEP. Studies have reported that 17-34% of patients had transient postoperative storage voiding complaints that may extend to 3 months following HoLEP. Storage symptoms are sometimes difficult to distinguish from UTI in the postoperative setting. (8-11)

Different scoring scales, such as BPH surgical scoring (BPHSS) system, have demonstrated modalities to predict perioperative outcomes of HoLEP; however, few studies have evaluated risk factors for postoperative UTI. Preoperative high postvoid residual (PVR), use of intermittent or indwelling catheterization, and Diabetes Mellitus (DM) have been proposed as predictors of UTI following transurethral prostate surgery. (12,13)

We aimed to study the incidence and risk factors for early storage urinary symptoms and postoperative UTI post-HoLEP in an attempt to decrease unnecessary postoperative antibiotic use and identifying high risk patient populations for UTI.

METHODS

A prospectively maintained database for patients undergoing HoLEP over five years was retrospectively reviewed. Study data were collected and managed using REDCap electronic data capture tool hosted at our institution. (14) The study protocol was approved by our Institutional Review Board. Patients without complete follow-up data at six weeks were excluded. Patients'

demographics, preoperative characteristics, operative and postoperative follow up data were obtained and analyzed. Postoperative UTI was defined by postoperative storage urinary symptoms with positive urine culture of >1,000 CFU/ml with identification of pathogenic organism. (15) Grip strength in association with hemoglobin level in last 30 days and the American Society of Anesthesiologists (ASA) physical status score were used for assessment of patient's frailty through Modified Hopkins frailty score adopted at our institution. (16,17)

HoLEP protocol

All HoLEP procedures were performed by a single surgeon (MET). Lumenis Pulse™ 120 H laser system and 550-micron laser fiber were used with energy settings of 80 and 40 W at a power setting of 2J and frequency of 40 and 20 HZ respectively. The protocol generally adopted for HoLEP procedures included preoperative urine culture for all the patients. Patients with preoperative positive urine culture were treated with appropriate antibiotics for 7 to 10 days without repeating the urine culture routinely after antibiotic use. Patients with indwelling urinary catheter were prescribed preoperative antibiotics only with positive urine culture. A single-dose intravenous antibiotic (3rd generation cephalosporins) was administered prior to anesthesia induction and prophylactic postoperative oral antibiotics (Sulfamethoxazole-Trimethoprim, Nitrofurantoin, Cephalexin or Ciprofloxacin) were given for three days to all patients. A voiding trial was usually performed on postoperative day 1. Patients were mostly discharged on a postoperative day 1 after passing the voiding trial. Patients who failed the voiding trial were discharged with an indwelling catheter and had a repeat voiding trial after 3 days in the outpatient clinic. During a 6-week postoperative follow up, clean catch mid-stream urine culture was ordered only for patients with suspected UTI. In the case of positive culture, antibiotics were prescribed according to culture and sensitivity results.

Statistical analysis

Sample characteristics were described using descriptive statistics. Frequencies and percentages were used to describe categorical variables. Means and standard deviations (or medians and ranges where appropriate) were used to describe continuous variables. Statistical analysis was performed using SAS 9.4. Logistic regression models were used to assess the association of different possible predictors to postoperative UTIs. The significance level was set to $p < 0.05$.

RESULTS

Of total 514 patients identified; 41 patients were excluded due to incomplete data. The data of 473 patients were included for analysis. Results of patient preoperative demographics are summarized in Table 1. Preoperative urine culture was positive in 135 (28.5%) patients. Patients were prescribed a preoperative fluoroquinolone (60%), Amoxicillin (17%), Sulfamethoxazole/trimethoprim (15%) or Nitrofurantoin (13%) to treat their preoperative positive urine culture. Around 81% of the patients had an ASA score of 2 or 3. HoLEP was

performed for 111 (23.4%) patients with retention at the time of surgery; 37 (7.8%) and 74 (15.6%) patients used clean intermittent catheterization and indwelling catheter respectively. Successful voiding trial and hospital discharge on postoperative day 1 was observed in 82% of the patients. Perioperative outcome data are shown in Table 2. Intraoperative complications were reported in 17 (3.59%) patients in the form of urethral injury (no=7), ureteric orifice injury (no=4), and bladder mucosal injury during morcellation (no=6). Up to 6-week postoperative follow up, 159 (33.61%) of patients reported urinary incontinence; differentially 67 (14.1%), 65 (13.7%) and 27 (5.7%) have stress, urge, and mixed type respectively. Storage urinary symptoms were reported in 153 (32.3%) patients, all of them had urine culture analysis. Within the patients with storage symptoms, they were associated with fever in 19 (12.42 %) patients and resulted in early clinic visits, ED visits, and readmission in 47 (30.72 %), 32 (20.92%), and 12 (7.84%) patients respectively. Among the patients who had urine culture, only 64 (13.5%) had positive postoperative urine culture among these patients. Table 3 shows the types of organism detected with urine culture in patients with postoperative UTI. Of note, changing the definition of UTI to the historic cut-off value for positive urine culture (>100,000 CFU/ml) would decrease the number of patients with postoperative positive urine culture to 57 (12%) instead of 64 (13.5%) patients.

With bivariate analysis, patients with postoperative UTI showed significantly higher BMI ($p = 0.023$), reduced grip strength at preoperative frailty assessment ($p = 0.042$), positive preoperative urine culture ($p = 0.025$), and postoperative urinary incontinence ($p = 0.002$). [Table 4] Multivariate regression analysis model using multiple variables again showed that high body mass index (BMI) (HR= 2.02; CI= 1.36-2.58, $p = 0.034$), preoperative positive urine culture (HR= 1.92; CI= 1.3-3.38, $p = 0.019$) and postoperative incontinence (HR= 2.82; CI= 1.8-5.67, $p = 0.015$) were associated with statistically significant risk of positive urine within 1st 6 weeks post-HoLEP.

DISCUSSION

Storage urinary symptoms continue to be a common postoperative complaint in the first 3 months following HoLEP. The reported incidence of storage urinary symptoms varies in different studied between 17% and 35%. (8-11) Differentiation of postoperative storage symptoms from UTI is usually difficult. Our results showed postoperative storage symptoms incidence of 32.3%, while UTI (positive urine culture) was observed in only 41% of these patients. This reiterates that patients are more likely to have transient complaints rather than infective processes. In the current study, we used the updated definition of the positive urine culture as “>1000 CFU/mL of a single bacteria in a urine culture in presence of new urinary tract symptoms” instead of the historic cut-off value of “>100,000 CFU/mL”. However, it may be prudent to consider using the >100,000 CFU/mL threshold in the setting of the postoperative period to minimize the use of antibiotics considering the abundance of lower urinary symptoms as shown in the current results.

Hwang et al, in their prospective study, have reported UTI incidence rate after transurethral prostate surgery of 34.9% with association to prolonged operation time and diabetes mellitus. They also have documented that the type of prophylactic antibiotic or length of antibiotic dose does not alter the postoperative infectious complication rate. (18) Kikuchi et al reported preoperative and postoperative incidence of UTI with HoLEP at 41% and 23% respectively. They showed that the risk of postoperative bacteriuria was lower with the use of perioperative prophylactic antibiotics and preoperative use of Dutasteride. They could not identify risk factors for postoperative infectious complications. (13)

At the current study, possible predictors of postoperative UTI include higher BMI ($p = 0.0231$), lessened grip strength, ($p = 0.0424$), and positive preoperative urine culture ($p = 0.025$). There is also a significant association between urinary incontinence and UTI at 6 weeks ($p = 0.0023$). Although there are no guideline recommendations or literature data regarding the indications of postoperative urine culture post-HoLEP, we recommend that these variables may help to guide clinical decision-making postoperatively to decrease the number of routine urine cultures. Multiple recent studies have shown correlation of the handgrip strength to the perioperative outcome of different surgeries in frail patients. (19,20) Surprisingly, some proposed clinical risk factors for UTI as intermittent or indwelling catheterization use, DM, and high PVR were not statistically linked to postoperative UTI in our patients. This may be attributed to more careful treatment of patients with a higher risk for UTI in the preoperative setting, preventing persistence of their UTI postoperatively.

Generally, guidelines currently recommend the use of single-dose antibiotic prophylaxis prior to all transurethral procedures for the treatment of enlarged prostate including HoLEP. (21,22) Recent prospective randomized studies have shown that preoperative prophylactic antibiotics can be safely omitted in patients without preoperative pyuria and a preoperative indwelling catheter undergoing TURP. (23) Currently, there is no clear evidence-based recommendations to guide the use of prophylactic postoperative antibiotics after HoLEP. Nevertheless, most surgeons performing HoLEP usually extend the antibiotics prophylaxis up to 3-7 days after HoLEP to avoid the incidence of urinary tract infection. (24, 25) The current article represents a novel work that has not been previously addressed in the growing field of HoLEP. The limitation of the study is the retrospective nature of the study. Future directed studies targeted to pre-and postoperative antibiotic use may elucidate further information on improvement on postoperative UTI rates and patient selection for urine culture post HoLEP.

CONCLUSIONS

It is key to have a high clinical suspicion for UTI post-HoLEP, however, it is equally important to keep in mind that more patients will present with transient complaints rather than UTIs. Storage symptoms can be associated with overtreatment by empirical antibiotics. Possible predictors of UTI after HoLEP are high BMI, preoperative positive urine culture, high frailty score, and postoperative urinary incontinence.

REFERENCES

1. Enikeev D, Taratkin M, Morozov A, Singla N, Gabdulina S, Tarasov A, et al. Long-Term Outcomes of Holmium Laser Enucleation of the Prostate: A 5-Year Single-Center Experience. *J Endourol*.2020;34:1055–1063.
2. Huang SW, Tsai CY, Tseng CS, Shih MC, Yeh YC, Chien KL, Pu YS, Tu YK. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. *BMJ*. 2019;367:l5919.
3. Gild P, Lenke L, Pompe RS, Vetterlein MW, Ludwig TA, Soave A, et al. Assessing the Outcome of Holmium Laser Enucleation of the Prostate by Age, Prostate Volume, and a History of Blood Thinning Agents: Report from a Single-Center Series of >1800 Consecutive Cases. *J Endourol*.2021;35:639–46.
4. Tamalunas A, Westhofen T, Schott M, Keller P, Atzler M, Stief CG, Magistro G. Holmium laser enucleation of the prostate: A truly size-independent method? *Low Urin Tract Symptoms*. 2022 Jan;14(1):17-26.
5. Jones P, Alzweri L, Rai BP, Somani BK, Bates C, Aboumarzouk OM. Holmium laser enucleation versus simple prostatectomy for treating large prostates: Results of a systematic review and meta-analysis. *Arab J Urol*. 2016 Mar;14(1):50-8.
6. Kuebker JM, Miller NL. Holmium Laser Enucleation of the Prostate: Patient Selection and Outcomes. *Curr Urol Rep* 2017; 18(12):96-017-0746-z.
7. Bae J, Choo M, Park JH, Oh JK, Paick JS, Oh SJ. Holmium laser enucleation of prostate for benign prostatic hyperplasia: seoul national university hospital experience. *Int Neurourol J* 2011;15(1):29-34.
8. Bae J, Choo M, Park JH, Oh JK, Paick JS, Oh SJ. Holmium laser enucleation of prostate for benign prostatic hyperplasia: seoul national university hospital experience. *Int Neurourol J* 2011;15(1):29-34.
9. Abdel-Hakim AM, Habib EI, El-Feel AS, Elbaz AG, Fayad AM, Abdel-Hakim MA, et al. Holmium laser enucleation of the prostate: initial report of the first 230 Egyptian cases performed in a single center. *Urology* 2010;76(2):448-452.
10. Elzayat EA, Habib EI, Elhilali MM. Holmium laser enucleation of the prostate: a size-independent new "gold standard". *Urology* 2005;66(5 Suppl):108-113.
11. Eltabey MA, Sherif H, Hussein AA. Holmium laser enucleation versus transurethral resection of the prostate. *Can J Urol* 2010;17(6):5447-5452.
12. Xu H, Cai Z, Chen Y, Gu M, Chen Q, Wang Z. Benign prostatic hyperplasia surgical scoring (BPHSS): a novel scoring system for the perioperative outcomes of holmium laser enucleation of the prostate. *Lasers Med Sci* 2018;33(3):589-595.
13. Kikuchi M, Kameyama K, Yasuda M, Yokoi S, Deguchi T, Miwa K. Postoperative infectious complications in patients undergoing holmium laser enucleation of the prostate: Risk factors and microbiological analysis. *Int J Urol* 2016;23(9):791-796.
14. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. 2019;95:103208.
15. Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2019 May 2;68(10):e83-e110.

16. Revenig LM, Canter DJ, Kim S, Liu Y, Sweeney JF, Sarmiento JM, et al. Report of a Simplified Frailty Score Predictive of Short-Term Postoperative Morbidity and Mortality. *J Am Coll Surg*. 2015 May;220(5):904-11.e1.
17. Mrdutt MM, Papaconstantinou HT, Robinson BD, Bird ET, Isbell CL. Preoperative Frailty and Surgical Outcomes Across Diverse Surgical Subspecialties in a Large Health Care System. *J Am Coll Surg*. 2019 Apr;228(4):482-490.
18. Hwang EC, Jung SI, Kwon DD, Lee G, Bae JH, Na YG, et al. A prospective Korean multicenter study for infectious complications in patients undergoing prostate surgery: risk factors and efficacy of antibiotic prophylaxis. *J Korean Med Sci*. 2014 ;29(9):1271-1277.
19. Marano L, Carbone L, Poto GE, Gambelli M, Nguefack Noudem LL, Grassi G, et al. Handgrip strength predicts length of hospital stay in an abdominal surgical setting: the role of frailty beyond age. *Aging Clin Exp Res*. 2022;34(4):811-817
20. Fountotos R, Munir H, Goldfarb M, Lauck S, Kim D, Perrault L, et al. Prognostic Value of Handgrip Strength in Older Adults Undergoing Cardiac Surgery. *Can J Cardiol*. 2021;37(11):1760-1766.
21. Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. *J Urol*. 2020;203(2):351-356.
22. Ivan SJ, Sindhvani P. Comparison of guideline recommendations for antimicrobial prophylaxis in urologic procedures: variability, lack of consensus, and contradictions. *Int Urol Nephrol*. 2018;50(11):1923-1937.
23. Baten E, Van Der Aa F, Goethuys H, Slabbaert K, Arijs I, van Renterghem K. Antimicrobial Prophylaxis in Transurethral Resection of the Prostate: Results of a Randomized Trial. *J Urol*. 2021 Jun;205(6):1748-1754.
24. Ishikawa K, Maruyama T, Kusaka M, Shiroki R, Hoshinaga K. The state of antimicrobial prophylaxis for holmium laser enucleation of the prostate: HoLEP and the results of a questionnaire survey. *Hinyokika Kiyo*. 2011 ;57(10):539-543. Japanese.
25. Davuluri M, Bernstein AP, Fram E, Watts KL. Variations in Perioperative Antibiotic Prescriptions Among Academic Urologists After Ambulatory Endoscopic Urologic Surgery: Impact on Infection Rates and Validation of 2019 Best Practice Statement. *Urology*. 2020; 146:101-106.

FIGURES AND TABLES

Variable	Patients (N=473)
Age, mean (SD)	71.69 (9.09)
BMI, median (IQR)	28.96 (6.42)
Prostate volume, gm, median (IQR)	89 (68–126)
PSA, ng/ml, median (IQR)	3.9 (1.75–7.6)
Retention at time of surgery, n (%)	111 (23.4%)
Duration of urine retention, days, median, (IQR)	60 (90)
CIC preop, n (%)	37 (7.8%)
Indwelling catheter, n (%)	74 (15.6%)
Diabetes mellitus, n, (%)	126 (26.63%)
Positive preop urine culture	135 (28.5)
PVR, ml, median (IQR)	135 (269)
Grip strength, PSI, median (IQR)	36 (14)
ASA score, n (%)	
	1 61(12.8%)
	2 191(40.38%)
	3 190 (40.16%)
	4 31(6.55%)

ASA: American Society of Anesthesiologists; BMI: body mass index; CIC: clean intermittent catheterization; PVR: postvoid residual.

Variable	Patients
Operative time, min, median (IQR)	65 (57–89)
Intraoperative complications, n (%)	17 (3.59%)
Pathological weight, median (IQR)	46 (52)
Catheterization time, days, mean (SD)	1.78 (2.2)
Failed 1 st voiding trial, n (%)	36 (7.61%)
Hospital-stay, days, mean (SD)	1.26 (1.38)
Immediate PVR, ml, median (IQR)	35 (19–75)
6-week IPSS score, median (IQR)	7 (4–11)
6-week QOL, median (IQR)	1 (0–3)
6-week storage urinary symptoms, n (%)	153 (32.3%)
6-week urinary tract infection, n (%)	64 (13.5%)
6-week urinary incontinence, n (%)	159 (33.61%)

6-week PVR, ml, median (IQR)	27 (63)
------------------------------	---------

IPSS: International Prostate Symptom Score, PVR: postvoid residual, QOL: quality of life; SD: standard deviation.

		Result
Organism, n (%)	<i>Enterococci faecalis</i>	15 (23.4%)
	<i>Escherichia coli</i>	13 (20.3%)
	<i>Staphylococci (aureus, coagulase negative)</i>	11 (17.1%)
	<i>Pseudomonas aeruginosa</i>	8 (12.5%)
	<i>Streptococci (Viridians, anginosus)</i>	7 (10.9%)
	<i>Proteus</i>	3 (4.6%)
	Other (<i>Enterobacter, Corynebacterium, Mixed, Candida</i>)	7 (10.9%)

Variable	PO UTI (no=64)	No PO UTI (no=409)	p
Age, mean, SD	70.95(9.48)	72.17(8.78)	0.315
BMI, median (IQR)	29(8.02)	27.88(6.35)	0.023
Retention at time of surgery, n (%)	23(35.9%)	130 (31.78%)	0.228
Urine retention duration, days, median (IQR)	70 (85)	60 (95)	0.871
CIC, n (%)	12 (18.75%)	67 (16.38%)	0.810
Diabetes mellitus, no (%)	22 (34.38%)	104 (25.4%)	0.158
Preop UTI, no (%)	22 (34.37%)	89(21.76%)	0.025
Intraoperative calculi, n (%)	3 (4.69%)	28 (6.94%)	0.508
Weight morcellated, gm, median (SD)	42(50)	46 (52)	0.332
Catheterization time, mean (SD)	1.55 (1.56)	1.79 (2.05)	0.369
Postoperative incontinence, no (%)	35 (54.68%)	124 (30.3%)	0.002
6 weeks PVR, ml, median (IGR)	23(69)	28(61)	0.387
Grip strength, median (IQR)	34(15)	39 (16)	0.042

ASA score, n (%)	1	6 (9.37)	56 (13.69)	0.783
	2	26 (40.6)	157 (38.39)	
	3	29 (45.31)	164 (40.09)	
	4	3 (4.68)	32 (7.82)	

ASA: American Society of Anesthesiologists; BMI: body mass index; CIC: clean intermittent catheterization; IQR: interquartile range; PVR: postvoid residual; SD: standard deviation; UTI: urinary tract infection

DRAFT